Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Robert T. McCormack"'
Autor:
Costanza Paoletti, Meredith M. Regan, Samuel M. Niman, Emily M. Dolce, Elizabeth P. Darga, Minetta C. Liu, P. Kelly Marcom, Lowell L. Hart, John W. Smith, Karen L. Tedesco, Eitan Amir, Ian E. Krop, Angela M. DeMichele, Pamela J. Goodwin, Margaret Block, Kimberly Aung, Martha E. Brown, Robert T. McCormack, Daniel F. Hayes
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-9 (2021)
Abstract Circulating tumor cells (CTC) are prognostic in metastatic breast cancer (MBC). The CTC-endocrine therapy index (CTC-ETI), consisting of CTC-ER (estrogen receptor), BCL2, human epidermal growth factor receptor (HER2), and Ki67 expression, mi
Externí odkaz:
https://doaj.org/article/a4591a6d3a9d4069a97a9133183bb04c
Autor:
Robert T. McCormack, Daniel Stetson, Dana E. Connors, J. Carl Barrett, Kenneth D. Cole, Steven P. Lund, Chris Karlovich, Thomas Forbes, P. Mickey Williams, Megan H. Cleveland, Laura M. Yee, Christie J. Lau, Cloud P. Paweletz, Gary J. Kelloff, Benoit Destenaves, Hua-Jun He, Susan M. Keating
Publikováno v:
JCO Precision Oncology
PURPOSEWe report the results from a Foundation for the National Institutes of Health Biomarkers Consortium project to address the absence of well-validated quality control materials (QCMs) for circulating tumor DNA (ctDNA) testing. This absence is co
Autor:
Martha E. Brown, Ian E. Krop, Eitan Amir, Margaret Block, Kimberly Aung, Karen L. Tedesco, Elizabeth P. Darga, Angela DeMichele, Meredith M. Regan, Costanza Paoletti, John W. Smith, Robert T. McCormack, Samuel M. Niman, Lowell L. Hart, Minetta C. Liu, Emily M. Dolce, Daniel F. Hayes, Pamela J. Goodwin, P. Kelly Marcom
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-9 (2021)
NPJ Breast Cancer
NPJ Breast Cancer
Circulating tumor cells (CTC) are prognostic in metastatic breast cancer (MBC). The CTC-endocrine therapy index (CTC-ETI), consisting of CTC-ER (estrogen receptor), BCL2, human epidermal growth factor receptor (HER2), and Ki67 expression, might predi
Autor:
J. Carl Barrett, Preeti Narayan, Soma Ghosh, Laurel J. Pracht, Gary J. Kelloff, Julia A. Beaver, Geoffrey R. Oxnard, Reena Philip, P. Mickey Williams, Justin I. Odegaard, Robert T. McCormack
Publikováno v:
Oncologist
With advances in precision oncology, liquid biopsies have shown promise as a minimally invasive means to diagnose cancer and guide treatment decisions. This commentary presents an assessment of the potential and the challenges of widespread use of li
Autor:
Gary J. Kelloff, Jennifer Boyle, Klaus Pantel, Dana E. Connors, Mark Stewart, Thomas Schlange, J.D. Alvarez, Susan M. Keating, Christian D. Rolfo, Lauren Leiman, Carolyn Hiller, Caroline C. Sigman, Massimo Cristofanilli, Jeff Allen, Emily Morgan, Diana M. Merino, Robert T. McCormack, María José Serrano, A. Pia Sanzone
Publikováno v:
Critical reviews in oncology/hematology. 156
The promise of precision medicine as a model to customize health care to the individual patient is heavily dependent upon new genetic tools to classify and characterize diseases and their hosts. Liquid biopsies serve as a safe alternative to solid bi
Autor:
Daniel F. Hayes, Robert T. McCormack
Comprehensive standards and guidelines for generating and reporting laboratory results are needed, especially as related to the translation of biology to precision medicine. This commentary focuses on the topic, highlighting a new study that investig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e46ea13129db4c29f0b8d9a46c6a47e
https://europepmc.org/articles/PMC7066685/
https://europepmc.org/articles/PMC7066685/
Autor:
Dana T. Aftab, Ana Limon-Carrera, Johann S. de Bono, M. Hirmand, Robert Dreicer, Ronald de Wit, Karim Fizazi, Arturo Molina, Fred Saad, Glenn Heller, Robert T. McCormack, Martin Fleisher, Thian Kheoh, Howard I. Scher, Matthew R. Smith
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 36(22)
Autor:
Glenn Heller, Mohammad Hirmand, Arturo Molina, Fred Saad, Robert T. McCormack, Dana T. Aftab, Thian Kheoh, Howard I. Scher, Johann S. de Bono, Karim Fizazi, Ana Limon, Martin Fleisher, Matthew R. Smith, Robert Dreicer, Ronald de Wit
Publikováno v:
Journal of Clinical Oncology, 36(6), 572-+. American Society of Clinical Oncology
Purpose Measures of response that are clinically meaningful and occur early are an unmet need in metastatic castration-resistant prostate cancer clinical research and practice. We explored, using individual patient data, week 13 circulating tumor cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b56e920755d1dd984613b57c43e43bc
https://pure.eur.nl/en/publications/666ccc8b-46c7-4918-9ed7-ec642e7956ea
https://pure.eur.nl/en/publications/666ccc8b-46c7-4918-9ed7-ec642e7956ea
Autor:
Daniel C. Danila, Johann S. de Bono, Mateus Crespo, David Olmos, Ines Figueiredo, Kurt Baeten, George Seed, Robert T. McCormack, Arturo Molina, Susana Miranda, Thian Kheoh, Howard I. Scher, Penny Flohr, Diletta Bianchini, Leon W.M.M. Terstappen, David Lorente, Joaquin Mateo, Martin Fleisher
Publikováno v:
EUROPEAN UROLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
European urology, 70(6), 985-992. Elsevier
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
European urology, 70(6), 985-992. Elsevier
Background: Treatment response biomarkers are urgently needed for castration-resistant prostate cancer (CRPC). Baseline and post-treatment circulating tumor cell (CTC) counts of >= 5 cells/7.5 ml are associated with poor CRPC outcome.Objective: To de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2854f01004b212e846268ec87cad1aec
http://www.europeanurology.com/article/S0302283816301877/pdf
http://www.europeanurology.com/article/S0302283816301877/pdf
Autor:
Arturo Molina, Ana Limon, Gary J. Kelloff, Matthew R. Smith, Fred Saad, Ronald de Wit, Robert T. McCormack, Howard I. Scher, Glenn Heller, Karim Fizazi, Robert Dreicer, Martin Fleisher, Dana T. Aftab, Johann S. de Bono
Publikováno v:
Journal of Clinical Oncology. 37:143-143
143 Background: Short-term measures of response that reflect clinical benefit are a critical unmet need for clinical trials for mCRPC. Using data from 5 randomized mCRPC trials, we showed that a response endpoint (RE) based on a change in CTC number